Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 22:12:890908.
doi: 10.3389/fonc.2022.890908. eCollection 2022.

Current and Emerging Prognostic Biomarkers in Endometrial Cancer

Kelechi Njoku  1   2   3 , Chloe E Barr  1   3 , Emma J Crosbie  1   3
Affiliations
Review

Current and Emerging Prognostic Biomarkers in Endometrial Cancer

Kelechi Njoku et al. Front Oncol. .

Abstract

Endometrial cancer is the most common gynaecological malignancy in high income countries and its incidence is rising. Whilst most women with endometrial cancer are diagnosed with highly curable disease and have good outcomes, a significant minority present with adverse clinico-pathological characteristics that herald a poor prognosis. Prognostic biomarkers that reliably select those at greatest risk of disease recurrence and death can guide management strategies to ensure that patients receive appropriate evidence-based and personalised care. The Cancer Genome Atlas substantially advanced our understanding of the molecular diversity of endometrial cancer and informed the development of simplified, pragmatic and cost-effective classifiers with prognostic implications and potential for clinical translation. Several blood-based biomarkers including proteins, metabolites, circulating tumour cells, circulating tumour DNA and inflammatory parameters have also shown promise for endometrial cancer risk assessment. This review provides an update on the established and emerging prognostic biomarkers in endometrial cancer.

Keywords: biomarkers; endometrial cancer; prognosis; risk stratification; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Current and emerging endometrial cancer prognostic biomarkers.
Figure 2
Figure 2
Defining the molecular subgroups of endometrial cancer based on the TransPORTEC classifier (A) and ProMisE (B). Adapted from (48, 49, 51).
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Crosbie E, Morrison J. The Emerging Epidemic of Endometrial Cancer: Time to Take Action. Cochrane Database Syst Rev (2014) 12:1465–858. doi: 10.1002/14651858.ED000095 - DOI - PMC - PubMed
    1. CRUK . Uterine Cancer Incidence Statistics. CRUK (2020). CRUK. Available at: www.cancerresearchuk.org; http://www.cancerresearchuk.org/health-professional/cancer-statistics/st... (Accessed 1/6/2020).
    1. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial Cancer. Lancet (2016) 387(10023):1094–108. doi: 10.1016/S0140-6736(15)00130-0 - DOI - PubMed
    1. Ryan NAJ, McMahon R, Tobi S, Snowsill T, Esquibel S, Wallace AJ, et al. The Proportion of Endometrial Tumours Associated With Lynch Syndrome (PETALS): A Prospective Cross-Sectional Study. PloS Med (2020) 17(9):e1003263. doi: 10.1371/journal.pmed.1003263 - DOI - PMC - PubMed

LinkOut - more resources